anti-epileptics Flashcards
mechanisms of anti-epileptics (5)
inactivate Na channels
inactivate Ca channels
reduce synaptic vesicle fusion
modulate glutamate receptors
modulate gaba receptors
pathophysiology of epilepsy
too much excitation or too little inhibition
are there increased or decreased levels of glutamate during seizures
increased
what is the ionotropic receptor type for GABA?
GABAA
what is the metabotropic receptor type for GABA
GABAB
targets of anti-epileptic drugs
glutamate- decrease activity at receptors
increase activity of GABA at receptors
Increase release of GABA
Inhibit breakdown of GABA
first line for treating status epilepticus
benzodiazepines: diazepam (valium), lorazepam (ativan)
first line of drug for absence seizures
ethosuximide
valproic acid
mechanism of benzodiazepines
increase affinity of GABA for the GABAA receptor
where are benzodiazepines metabolized
liver
side effects of benzodiazepines
sedative
withdrawal symptoms due to tolerance
mechanism of vigabatrin
inhibit GABA-T to reduce GABA breakdown
indication for vigabatrin (sabril)
complex partial seizures that are refractory to several others AEDs
infantile spasms
drug interaction of vigabatrin
reduces plasma concentration of primidone
side effects of vigabatrin
concentric visual field deficit (can be irreversible)
drowsiness
dizzinesss
weight gain
what is carbamazepine indicated for
focal seizures and GTCSs
mechanism of carbamazepine
block tetanic firing
increases Na channel inactivation, reduces transmitter release
potentiates GABA response
what is carbamazepine used for other than seizures
bipolar disorder
carbamazepine toxicities
ataxia, diplopia, nystagmus, dizziness
tolerance to side effects
aplastic anemia
rash- Stevens Johnson Syndrome, Toxic Epidermal Necrolysis
what drugs should never be used with carbamazepine
drugs that inhibit hepatic metabolism- increases toxicity
mechanism of phenytoin (dilantin)
blocks tetanic firing
increases Na channel inactivation
releases neurotransmitter release
indication for phenytoin
focal seizures and GTCSs
status epilepticus
notable phamacokinetic aspect of phenytoin
oral absorption peak time variable from patient to patient, difficult to get dosing within therapeutic range
functions at 1st order kinetic at low doses and zero order kinetics at high doses
side effects of phenytoin
cardiac arrhythmias
dizziness
nystagmus
headaches
rash
gingival hyperplasia and hirsutism